Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes
<p>Abstract</p> <p>Background</p> <p>Our objective was to determine the cost-effectiveness of Continuous Glucose Monitoring (CGM) technology with intensive insulin therapy compared to self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes in the United S...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-09-01
|
Series: | Cost Effectiveness and Resource Allocation |
Subjects: | |
Online Access: | http://www.resource-allocation.com/content/9/1/13 |
_version_ | 1818083039397281792 |
---|---|
author | Nair Kavita V Campbell Jonathan D Ellis Samuel L McQueen R Brett Sullivan Patrick W |
author_facet | Nair Kavita V Campbell Jonathan D Ellis Samuel L McQueen R Brett Sullivan Patrick W |
author_sort | Nair Kavita V |
collection | DOAJ |
description | <p>Abstract</p> <p>Background</p> <p>Our objective was to determine the cost-effectiveness of Continuous Glucose Monitoring (CGM) technology with intensive insulin therapy compared to self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes in the United States.</p> <p>Methods</p> <p>A Markov cohort analysis was used to model the long-term disease progression of 12 different diabetes disease states, using a cycle length of 1 year with a 33-year time horizon. The analysis uses a societal perspective to model a population with a 20-year history of diabetes with mean age of 40. Costs are expressed in $US 2007, effectiveness in quality-adjusted life years (QALYs). Parameter estimates and their ranges were derived from the literature. Utility estimates were drawn from the EQ-5D catalogue. Probabilities were derived from the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Costs and QALYs were discounted at 3% per year. Univariate and Multivariate probabilistic sensitivity analyses were conducted using 10,000 Monte Carlo simulations.</p> <p>Results</p> <p>Compared to SMBG, use of CGM with intensive insulin treatment resulted in an expected improvement in effectiveness of 0.52 QALYs, and an expected increase in cost of $23,552, resulting in an ICER of approximately $45,033/QALY. For a willingness-to-pay (WTP) of $100,000/QALY, CGM with intensive insulin therapy was cost-effective in 70% of the Monte Carlo simulations.</p> <p>Conclusions</p> <p>CGM with intensive insulin therapy appears to be cost-effective relative to SMBG and other societal health interventions.</p> |
first_indexed | 2024-12-10T19:31:39Z |
format | Article |
id | doaj.art-72fd75fc68e94265b2eb0845e1a20cb4 |
institution | Directory Open Access Journal |
issn | 1478-7547 |
language | English |
last_indexed | 2024-12-10T19:31:39Z |
publishDate | 2011-09-01 |
publisher | BMC |
record_format | Article |
series | Cost Effectiveness and Resource Allocation |
spelling | doaj.art-72fd75fc68e94265b2eb0845e1a20cb42022-12-22T01:36:14ZengBMCCost Effectiveness and Resource Allocation1478-75472011-09-01911310.1186/1478-7547-9-13Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetesNair Kavita VCampbell Jonathan DEllis Samuel LMcQueen R BrettSullivan Patrick W<p>Abstract</p> <p>Background</p> <p>Our objective was to determine the cost-effectiveness of Continuous Glucose Monitoring (CGM) technology with intensive insulin therapy compared to self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes in the United States.</p> <p>Methods</p> <p>A Markov cohort analysis was used to model the long-term disease progression of 12 different diabetes disease states, using a cycle length of 1 year with a 33-year time horizon. The analysis uses a societal perspective to model a population with a 20-year history of diabetes with mean age of 40. Costs are expressed in $US 2007, effectiveness in quality-adjusted life years (QALYs). Parameter estimates and their ranges were derived from the literature. Utility estimates were drawn from the EQ-5D catalogue. Probabilities were derived from the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Costs and QALYs were discounted at 3% per year. Univariate and Multivariate probabilistic sensitivity analyses were conducted using 10,000 Monte Carlo simulations.</p> <p>Results</p> <p>Compared to SMBG, use of CGM with intensive insulin treatment resulted in an expected improvement in effectiveness of 0.52 QALYs, and an expected increase in cost of $23,552, resulting in an ICER of approximately $45,033/QALY. For a willingness-to-pay (WTP) of $100,000/QALY, CGM with intensive insulin therapy was cost-effective in 70% of the Monte Carlo simulations.</p> <p>Conclusions</p> <p>CGM with intensive insulin therapy appears to be cost-effective relative to SMBG and other societal health interventions.</p>http://www.resource-allocation.com/content/9/1/13Cost-effectiveness analysisContinuous Glucose MonitoringType 1 diabetesCost-utility analysisSelf-Monitoring of Blood Glucose |
spellingShingle | Nair Kavita V Campbell Jonathan D Ellis Samuel L McQueen R Brett Sullivan Patrick W Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes Cost Effectiveness and Resource Allocation Cost-effectiveness analysis Continuous Glucose Monitoring Type 1 diabetes Cost-utility analysis Self-Monitoring of Blood Glucose |
title | Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes |
title_full | Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes |
title_fullStr | Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes |
title_full_unstemmed | Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes |
title_short | Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes |
title_sort | cost effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes |
topic | Cost-effectiveness analysis Continuous Glucose Monitoring Type 1 diabetes Cost-utility analysis Self-Monitoring of Blood Glucose |
url | http://www.resource-allocation.com/content/9/1/13 |
work_keys_str_mv | AT nairkavitav costeffectivenessofcontinuousglucosemonitoringandintensiveinsulintherapyfortype1diabetes AT campbelljonathand costeffectivenessofcontinuousglucosemonitoringandintensiveinsulintherapyfortype1diabetes AT ellissamuell costeffectivenessofcontinuousglucosemonitoringandintensiveinsulintherapyfortype1diabetes AT mcqueenrbrett costeffectivenessofcontinuousglucosemonitoringandintensiveinsulintherapyfortype1diabetes AT sullivanpatrickw costeffectivenessofcontinuousglucosemonitoringandintensiveinsulintherapyfortype1diabetes |